BeneFIX

nonacog alfa · Pfizer Europe MA EEIG
AUTHORISED IN THE EU

What BeneFIX is used for

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor-IX deficiency).

Approved use, as published by the European Medicines Agency.

Key facts

Brand
BeneFIX
Active substance
nonacog alfa
Disease area
Hemophilia B
Medicine group
Antihemorrhagics
ATC code
B02BD04
Marketing authorisation holder
Pfizer Europe MA EEIG
Authorised in the EU since
1997

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is BeneFIX used for?

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor-IX deficiency).

What is the active substance in BeneFIX?

BeneFIX contains nonacog alfa.

Who makes BeneFIX?

The EU marketing authorisation holder is Pfizer Europe MA EEIG.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.